Clinical Trials for Patients with Relapsing Multiple Sclerosis
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects with Relapsing-Remitting Multiple Sclerosis
Biogen 205MS303 EXTEND
A Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Have Completed Study 205MS301
A Multicenter, Observational, Open-Label, Single-Arm Study
of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
* Genentech MN30035 CHORDS
Open-label study to evaluate the effectiveness and safety of Ocrelizumab in patients with RRMS who have had a suboptimal response to an adequate course of disease-modifying treatment
Open-label, single-arm study to evaluate the effectiveness and safety of Ocrelizumab in patients with early stage RRMS
Genzyme CAMMS03409 Campath Extension Study
An Extension Protocol For Multiple Sclerosis Patients Who Participated in Genzyme Sponsored Studies of Alemtuzumab (Protocol # CAMMS03409; also known as the CARE-MSSM Extension Study)
Multicenter, open-label, concomparative study to evaluate the long-term safety, efficacy and self-reported quality of life of Alemtuzumab in patients who have completed at least 48 months of the extension study CAMMS03409
* Novartis COMB157G2302 ASCLEPIOS
A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of Ofatumumab (once monthly SC injection) versus Teriflunomide (Aubagio) in patients with RRMS
A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sclerosis
Observational Trials for Patients with Relapsing Multiple Sclerosis
All patients starting Tecfidera, Plegridy and Gilenya are asked to participate in the below Phase IV observational clinical trials.
A Real World, Prospective, Single-center, Observational Study Evaluating the Safety of OCREVUS in Patients with Relapsing and Progressive Multiple Sclerosis with Advanced Age and EDSS Score.
A Multicenter, Global, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Tecfidera™ (Dimethyl Fumarate) When Used in Routine Medical Practice in the Treatment of Multiple Sclerosis (ESTEEM)Additional information on this clinical trial can be found here.
* Biogen 105MS401 POP
Plegridy™ (peginterferon β-1a) Real World Effectiveness and Safety Observational Program
*Genzyme IVSS (OBS14379): A prospective observational cohort study in adult patients with relapsing multiple sclerosis to further characterize the safety profile of Lemtrada by vital sign monitoring during and after all infusions comprising the first treatment course.
*Genzyme PASS (OBS13434)
A prospective, multicenter, observational post-authorization safety study to evaluate the long-term safety profile of Lemtrada treatment in patients with RRMS
*Novartis CFTY720DUS40 FLUENT
A 12-Month, prospective, multicenter, two-cohort, nonrandomized, open-label study in adult patients with Relapsing Multiple Sclerosis (RMS), to investigate changes in immune phenotype biomarkers after treatment with 0.5 mg fingolimod (FTY720)
* Novartis FTY2403 PASSAGE
Long-term, prospective, multinational, parallel-cohort study monitoring safety in patients with MS newly started with fingolimod once daily or treated with another approved disease-modifying therapyAdditional information on this clinical trial can be found here.
A two-year observational study to evaluate the safety profile of fingolimod in patients with multiple sclerosis who switch from natalizumab to fingolimod
Additional information on this clinical trial can be found here.
Corrona MS Registry is a prospective, non-interventional, research study for patients with MS under the care of a board-certified neurologist. The primary objective for this registry is to prospectively study the natural history of MS, the prevalence and incidence of comorbidities, and targeted adverse events, as well as the utilization patterns and the comparative effectiveness and comparative safety of approved MS treatments.
Retrospective Clinical Trials
IMS PROTRACT (MS200136_0037): A retrospective (chart-review) study investigating real world clinical, neurological, tolerability, and safety outcomes of patients whose first disease modifying therapy was Rebif vs. Tecfidera